Childhood leukemias in Mexico: towards implementing CAR-T cell therapy programs

Area of Science:

• Pediatric Oncology
• Hematological Malignancies
• Cell and Gene Therapy

Background:

• Leukemias are the most frequent pediatric cancers globally, with improving but still challenging prognoses for refractory cases.
• Conventional treatments like chemotherapy are effective, but novel strategies such as immunotherapy, including CAR-T cells, are crucial for relapsed or refractory disease.
• CAR-T cell therapies have demonstrated clinical efficacy and received regulatory approval, yet global accessibility remains a significant concern, especially in low- and middle-income countries.

Purpose of the Study:

• To provide an overview of childhood leukemias in Mexico.
• To discuss current strategies, advancements, and challenges in making cell and gene therapies available for leukemia patients in Mexico.
• To highlight the ongoing efforts to improve access to CAR-T cell therapy for Mexican patients.

Main Methods:

• Review of current literature on pediatric leukemia treatment and immunotherapy.
• Analysis of the landscape of leukemia diagnosis and treatment in Mexico.
• Exploration of strategies and challenges for implementing advanced therapies like CAR-T cells in Mexico.

Main Results:

• Childhood leukemias constitute approximately 50% of pediatric cancers in Mexico.
• Mexico faces a higher rate of relapsed or refractory leukemia compared to international reports.
• Significant progress in leukemia treatment has been made, with cell and gene therapies on the horizon for Mexican patients.

Conclusions:

• Making advanced therapies like CAR-T cell therapy accessible to Mexican patients is a priority.
• Ongoing efforts aim to overcome challenges and improve the availability of gene and cell therapies for childhood leukemia in Mexico.
• Addressing the multi-factorial problem of higher relapsed/refractory disease rates is essential for improving outcomes.